> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 11 Observations in Eugia Pharma Inspection
- URL: https://www.fdaweb.com/11-observations-in-eugia-pharma-inspection/
- Published: 2026-02-12T12:00:00.000Z
- Updated: 2026-09-14T13:33:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160663

FDA has released a 29-page form[ FDA-483 ](https://www.fda.gov/media/191109/download?ref=fdaweb.com)with 11 observations from a 1/27-2/6 inspection at the Eugia Pharma Specialties sterile drug product manufacturing facility in Sangareddy, Telangana, India. The inspection observations were:

- failure to establish and follow written procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- failure of procedures designed to prevent microbiological contamination of drug products purporting to be sterile, to include adequate validation of the aseptic process;
- failure to fully follow the responsibilities and procedures of the quality control unit;
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- failure of testing and release of drug product for distribution to include appropriate laboratory determination of satisfactory conformance to the final specifications before release;
- failure to train employees in the particular operations they perform as part of their function;
- failure to follow test procedures relative to appropriate laboratory testing for pyrogens;
- aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions;
- failure of laboratory records to include the initials or signature of a second person showing that the original records have been reviewed for accuracy; and
- failure to follow established laboratory control mechanisms.